I don't really know which piece of the puzzle
is more important--the regulation, like Ariad
has...or the vector, like many of the AAV players
seem to have now. The Genovo hybrid AAV might be
especially interesting, but I've not done
the sort of DD into that I should have by
now...I'm such a damn gambler. After the
Avigen/Aria hullaballo, I sort of walked away
from the discussion of who has the best vector.
Somebody call one of the pros at BBRS and just
ask for a straight answer--Who has the best vector
right now Mr. Silverman? Mr. King?
A smart fellow would buy a little of each,
and forget about them--the real payoffs are
at least several years away. In the meantime,
trade half your shares for entertainment. TGEN
pops up a few times a year, that's a good one
to hold shares for news related pops.
This weekend I should review Valentis'
(Gene Medicine) Gene Switch--in fact, they
have another PR about it today, another
patent.
I am very happy to make guesses about what is
the important piece though. And my guess is that
the Ariad dimerizer stuff really is every bit as
slick as it seems to be. Oh, it might be five years
before we know for sure--but I think we all know
this thing about finances, or partners or a buyout
will certainly be resolved well before the first
therapies are approved.
A biotech with anything at all real going on is
worth more than 25M. Ariad is worth 100M. Too bad
I'm the only one who seems to feel that way right now,
and everybody else owns the others, safety in numbers,
fine.
So like I said, buy a little of each. Nobody should
be like me and go all out on one, that's just damn
foolish--which I am. |
